Calypte Biomedical To Host Conference Call
July 21 2004 - 4:03PM
PR Newswire (US)
Calypte Biomedical To Host Conference Call CEO to Discuss The
International AIDS Conference and Recent Clinical Data Disclosed at
Event PLEASANTON, Calif., July 21 /PRNewswire-FirstCall/ -- Calypte
Biomedical Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) ,
announced today that Dr. Richard George, Calypte's President and
Chief Executive Officer, will host a conference call on Thursday
morning at 11:00 am EDT to discuss the recently concluded XV
International AIDS Conference in Bangkok, Thailand, as well as
provide an in-depth discussion of the recently released data from
the Thailand field trials on the Company's HIV-1/2 rapid urine,
oral fluid and blood tests. Investors in the U.S. and Canada
interested in participating in the conference call may dial
800-915-4836 and reference the Calypte Biomedical call.
International investors may dial 973-317-5319. A live webcast of
the conference call accompanied by a moderator activated slide
presentation will be available at
http://www.shareholder.com/calypte/medialist.cfm . The webcast will
be available until August 5, 2004. A replay of the call will be
available through August 5, 2004 by calling 888-203-1112 in the
U.S. and Canada and 719-457-0820 for international listeners. The
replay confirmation code is 693031. The quarterly investors' call
on the results of the second quarter ended June 30, 2004 will be
held as a separate call on August 12, 2004. ABOUT CALYPTE
BIOMEDICAL: Calypte Biomedical Corporation, headquartered in
Pleasanton, California, is a public healthcare company dedicated to
the development and commercialization of in vitro diagnostic tests,
primarily for the detection of antibodies to Human Immunodeficiency
Virus (HIV), and other sexually transmitted and infectious
diseases. Calypte's currently marketed laboratory- based tests
include an enzyme immunoassay (EIA) HIV-1 antibody screening test
and an HIV-1 antibody western blot supplemental test, the only two
FDA- approved HIV-1 antibody tests for use on urine samples, as
well as an FDA- approved serum HIV-1 antibody western blot
supplemental test. Calypte is actively engaged in developing new
test products for the rapid detection of HIV and other infectious
diseases. Calypte believes that there is a significant need for
rapid detection of such diseases globally to control their
proliferation, particularly in lesser-developed countries, which
lack the medical infrastructure to support laboratory-based
testing. Calypte believes that testing for HIV and other infectious
diseases may make important contributions to public health.
CONTACT: Dr. Richard George, President and CEO Calypte Biomedical
Corp. 925.730.7200 Tim Clemensen Rubinstein Investor Relations
212.843.9337 DATASOURCE: Calypte Biomedical Corporation CONTACT:
Dr. Richard George, President and CEO of Calypte Biomedical Corp.,
+1-925-730-7200, ; or Tim Clemensen, of Rubinstein Investor
Relations, +1-212-843-9337, for Calypte Biomedical Corporation Web
site: http://www.calypte.com/
http://www.shareholder.com/calypte/medialist.cfm
Copyright